Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor of Orthopaedic and Tropical Surgery and Consultant Orthopaedic and Spine Surgeon Chris Lavy has been awarded a prestigious honorary fellowship by the British Orthopaedic Association (BOA).

Photo of Chris Lavy

An Honorary Fellowship is the highest honour that the BOA offer, and is awarded to individuals who have made outstanding contributions to trauma and orthopaedics.

Professor Lavy's clinical interests include surgery of the spine, hip and knee, and his research interests focus on surgery in Africa and the Tropics. He leads the NDORMS Lavy Global Surgery group which is deeply involved in research, teaching and training to strengthen surgical care and training capacity in Africa. This includes SURG-AFRICA, which is focused on scaling up safe surgery in district hospitals to make it accessible to otherwise neglected rural populations, and clubfoot training and research to help to improve treatment for children born with clubfoot in Africa.

One of his newest emerging areas of research is into treatments that could improve the recovery rate from spinal cord injuries.

Candidates for Honorary Fellowships are considered annually by a Board comprising the last five BOA Presidents and usually presented to recipients by the President at the annual BOA Congress.

Due to the coronavirus pandemic, Prof Lavy was presented with the award virtually at this year's BOA conference, and will receive the award in person at the BOA Congress in Aberdeen next September.

Similar stories

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?